Bryan Dechairo, PhD

The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis

Background: Pharmacogenomic (PGx) testing is a potential tool to inform clinicians’ treatment decisions for patients with Major Depressive Disorder (MDD). However, there is mixed evidence...

Ken Yu , MS;

Holly Johnson , PhD;

Krystal Brown , PhD;

Michael Jablonski , PhD;

Bryan Dechairo , PhD;

Lisa Brown , PhD;

Oliver Vranjkovic , PhD;

James Li , MS, PhD;

10/08/2020

Using a Genetic Test (Combinatorial Pharmacogenomics)To Help Choose Patient-Specific Antidepressants for Depression: a Large, Blinded, Randomized Control Trial

Background: Here we present the first prospective, large-scale, patient- and rater-blind, randomized controlled trial evaluating the utility of combinatorial pharmacogenomic (PGx) testing...

Anthony Rothschild , MD;

Boadie Dunlop , MD;

Michael Thase , MD;

Charles Conway , MD;

Richard Shelton , MD;

Brent Forester , MD, MSc;

James Li , MS, PhD;

Francis Mondimore , MD;

Krystal Brown , PhD;

Matthew Macaluso , DO;

Michael Jablonski , PhD;

Alexa Gilbert , MSc, MBA;